Two Phase 2 Trials to Assess Production of Dystrophin in Patients with Nonsense Mutation Duchenne Muscular Dystrophy Receiving Ataluren

被引：0
|
作者：
Nelson, S.
Penematsa, V
Chou, C.
Trifillis, P.
Bibbiani, F.
McIntosh, J.
机构：
来源：
ANNALS OF NEUROLOGY | 2019年 / 86卷
关键词：
Neuromuscular Disorders; Rare Diseases;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
186
引用
收藏
页码：S127 / S127
页数：1
相关论文
共 50 条
  • [21] Ataluren Delays Loss of Ambulation and Decline in Pulmonary Function in Patients with Nonsense Mutation Duchenne Muscular Dystrophy
    McDonald, Craig
    Muntoni, Francesco
    Rance, Mark
    Jiang, Joel
    Kristensen, Allan
    Penematsa, Vinay
    Bibbiani, Francesco
    Goodwin, Elizabeth
    Gordish-Dressman, Heather
    Morgenroth, Lauren
    Able, Richard
    Trifillis, Panayiota
    Tulinius, Mar
    NEUROLOGY, 2021, 96 (15)
  • [22] Ataluren Confirmatory Trial in DMD: Effect of Ataluren on Activities of Daily Living in Nonsense Mutation Duchenne Muscular Dystrophy
    Quinlivan, Ros
    Luo, Xiaohui
    Elfring, G.
    Kroger, Hans
    Riebling, Peter
    Ong, Tuyen
    Spiegel, Robert
    Peltz, Stuart
    Kirschner, Jan
    NEUROLOGY, 2016, 86
  • [23] ACT DMD: effect of ataluren on timed function tests in nonsense mutation Duchenne muscular dystrophy
    Bushby, K.
    Campbell, C.
    McDonald, C. M.
    Voit, T.
    Luo, X.
    Elfring, G.
    Kroger, H.
    Riebling, P.
    Ong, T.
    Spiegel, R.
    Peltz, S. W.
    Goemans, N.
    NEUROMUSCULAR DISORDERS, 2016, 26 : S5 - S5
  • [24] Improvements in health status and utility associated with ataluren for the treatment of nonsense mutation Duchenne muscular dystrophy
    Landfeldt, Erik
    Lindberg, Christopher
    Sejersen, Thomas
    MUSCLE & NERVE, 2020, 61 (03) : 363 - 368
  • [25] Ataluren use in patients with nonsense mutation Duchenne muscular dystrophy: patient demographics and characteristics from the STRIDE Registry
    Muntoni, Francesco
    Desguerre, Isabelle
    Guglieri, Michela
    Nascimento Osorio, Andres
    Kirschner, Janbernd
    Tulinius, Mar
    Buccella, Filippo
    Elfring, Gary
    Werner, Christian
    Schilling, Traci
    Trifillis, Panayiota
    Zhang, Olivia
    Delage, Abdallah
    Santos, Claudio L.
    Mercuri, Eugenio
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (14) : 1187 - 1200
  • [26] DEMOGRAPHICS AND SAFETY DATA FROM PATIENTS WITH NONSENSE MUTATION DUCHENNE MUSCULAR DYSTROPHY RECEIVING ATALUREN IN THE STRATEGIC TARGETING OF REGISTRIES AND INTERNATIONAL DATABASE OF EXCELLENCE
    Muntoni, Francesco
    Buccella, Filippo
    Desguerre, Isabelle
    Kirschner, Janbernd
    Osorio, Andres Nascimento
    Tulinius, Mar
    Jiang, Joel
    Kristensen, Allan
    Able, Richard
    Trifillis, Panayiota
    Santos, Claudio
    MUSCLE & NERVE, 2020, 62 : S57 - S58
  • [27] Design of a phase 3 trial to evaluate the long-term efficacy and safety of ataluren in patients with nonsense mutation Duchenne muscular dystrophy
    Riebling, P.
    O'Mara, E.
    Luo, X.
    Trifillis, P.
    Ong, T.
    NEUROMUSCULAR DISORDERS, 2017, 27 : S218 - S218
  • [28] DESIGN OF A PHASE 3 TRIAL TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF ATALUREN IN PATIENTS WITH NONSENSE MUTATION DUCHENNE MUSCULAR DYSTROPHY
    Trifillis, Panayiota
    Schilling, Traci
    O'Mara, Edward
    McIntosh, Joseph
    MUSCLE & NERVE, 2018, 58 : S59 - S59
  • [29] Design of a Phase 3 Trial to Evaluate the Long-Term Efficacy and Safety of Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy
    Trifillis, Panayiota
    Riebling, Peter
    O'Mara, Edward
    Luo, Xiaohui
    McIntosh, Joseph
    NEUROLOGY, 2018, 90
  • [30] A mini-review and implementation model for using ataluren to treat nonsense mutation Duchenne muscular dystrophy
    Landfeldt, Erik
    Sejersen, Thomas
    Tulinius, Mar
    ACTA PAEDIATRICA, 2019, 108 (02) : 224 - 230
12345